causal
Procedural irregularity causes rational hesitancy
When the FDA cuts procedural corners or approves on weak evidence—as in the controversial eteplirsen/Exondys approval for Duchenne muscular dystrophy over advisory-committee and division-director objections—it can produce rational hesitancy among informed purchasers, exemplified by insurers refusing to cover the drug because they don't know whether it works; this differs from psychologically driven vaccine hesitancy.
causalpending
Speaker
Daniel CarpenterEvidence Quote
“These are informed purchasers. So, part of what happens when you have procedural irregularity or corners cut or bad evidence underlying approval decisions is, you get, in some cases, what might be rational hesitancy on the part of treatments.”
Created: 6/13/2026, 3:23:23 AM
Your notes
Loading notes...